DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Sandhu SK, Schelman WR, Wilding G. et al.
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Lancet Oncol 2013;
14: 882-892
DOI: 10.1016/S1470-2045(13)70240-7.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.